tbuckley/cabot-search huggingface dataset:
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial
Authors: Ralf U. Trappe, Daan Dierickx, Heiner Zimmermann, Franck Morschhauser, Peter Mollee, Jan M. Zaucha, Martin H. Dreyling, Ulrich Dührsen, Petra Reinke, Gregor Verhoef, Marion Subklewe, Andreas Hüttmann, Thomas Tousseyn, Gilles Salles, Volker Kliem, Ingeborg A. Hauser, Corrado Tarella, Eric Van Den Neste, Olivier Gheysens, Ioannis Anagnostopoulos, Veronique Leblond, Hanno Riess, Sylvain Choquet
Journal: Journal of Clinical Oncology (2017)

Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified response to rituximab induction as a prognostic factor for overall survival. We hypothesized that rituximab consolidation might be sufficient treatment for patients with a complete response after rituximab induction. Patients and Methods In this prospective, international, multicenter phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20 + PTLD unresponsive to immunosuppression reduction, were treated with four weekly doses of rituximab induction. After restaging, complete responders continued with four courses of rituximab consolidation every 21 days; all others received four courses of rituximab plus CHOP chemotherapy every 21 days. The primary end point was treatment efficacy measured as the response rate in patients who completed therapy and the response duration in those who completed therapy and responded. Secondary end points were frequency of infections, treatment-related mortality, and overall survival in the intention-to-treat population. Results One hundred eleven of 126 patients had a complete or partial response (88%; 95% CI, 81% to 93%), of whom 88 had a complete response (70%; 95% CI, 61% to 77%). Median response duration was not reached. The 3-year estimate was 82% (95% CI, 74% to 90%). Median overall survival was 6.6 years (95% CI, 5.5 to 7.6 years). The frequency of grade 3 or 4 infections and of treatment-related mortality was 34% (95% CI, 27% to 42%) and 8% (95% CI, 5% to 14%), respectively. Response to rituximab induction remained a prognostic factor for overall survival despite treatment stratification. Conclusion In B-cell PTLD, treatment stratification into rituximab or rituximab plus CHOP consolidation on the basis of response to rituximab induction is feasible, safe, and effective.
Rates of Non-Transfusional Iron Accumulation (NTIA) In Hemoglobin E Thalassemia
Authors: Nancy F. Olivieri, Vivekanandan Thayalasuthan, Giulia Muraca, David J Weatherall, Cecilia Kim, Anuja Premawardhena, Ashok Perera, Angela O'Donnell, Timothy St. Pierre
Journal: Blood (2010)
5q- Myelodysplastic Syndrome, In One of 23 Children Lacking a Known Ribosomal Gene Mutation, Masquerading as Diamond Blackfan Anemia (DBA) and Responding to Lenalidomide
Authors: Adrianna Vlachos, Jason Farrar, Eva Atsidaftos, Ellen Muir, Thomas C. Markello, Sharon Singh, Johnson M. Liu, Steven Ellis, Robert J. Arceci, David M. Bodine, Jeffrey Michael Lipton
Journal: Blood (2010)
Targeting CXCR4, SDF1 and Beta-Adrenergic Receptors In the AML Microenvironment by Novel Antagonist POL6326, G-CSF and Isoproterenol
Authors: Ye Chen, Zhihong Zeng, Yuexi Shi, Rodrigo Jacamo, Christian Ludin, Klaus Dembowsky, Paul S. Frenette, Marina Konopleva, Michael Andreeff
Journal: Blood (2010)
Prophylactic Effect of Oral Acetazolamide against Intraocular Pressure Elevation after Cataract Surgery in Eyes with Glaucoma
Authors: Ken Hayashi, Motoaki Yoshida, Shin-ichi Manabe, Koichi Yoshimura
Journal: Ophthalmology (2017)

To confirm the prophylactic effect of oral acetazolamide against increased intraocular pressure (IOP) in the period immediately after cataract surgery in eyes with primary open-angle glaucoma (POAG) and to evaluate the appropriate administration time of oral acetazolamide to prevent IOP elevation.Randomized clinical study.Ninety eyes of 90 patients with well-controlled POAG scheduled for phacoemulsification.Eyes were assigned randomly to 1 of 3 groups: (1) oral acetazolamide (500 mg) administration 1 hour preoperatively, (2) oral acetazolamide (500 mg) administration 3 hours postoperatively, or (3) no acetazolamide administration. Intraocular pressure was measured using a rebound tonometer 1 hour preoperatively, at the conclusion of surgery (adjusted in the range between 15 and 25 mmHg), and 1, 3, 5, 7, and 24 hours postoperatively. The incidence of eyes with IOP elevation more than 100% above the preoperative IOP was compared.Postoperative IOP and incidence of eyes with marked IOP elevation.Mean IOP 1 hour preoperatively and that at the conclusion of surgery did not differ significantly among groups. In all groups, mean IOP was significantly elevated from 3 to 7 hours postoperatively, and then decreased at 24 hours. At 1 and 3 hours postoperatively, mean IOP was significantly lower in the group receiving oral acetazolamide preoperatively than in the other 2 groups (postoperative administration or no administration; P ≤ 0.0031). At 5, 7, and 24 hours postoperatively, the IOP was significantly lower in both the preoperative and postoperative administration groups than in the nonadministration group (P ≤ 0.0224). Intraocular pressure elevation of more than 100% occurred in 1 eye (3.3%) in the preoperative administration group, 7 eyes (23.3%) in the postoperative administration group, and 8 eyes (26.6%) in the nonadministration group; the incidence was significantly lower in the preoperative administration group (P = 0.0459).Eyes with POAG experienced short-term IOP elevation from 3 to 7 hours after phacoemulsification. Oral acetazolamide administration 1 hour preoperatively significantly reduced the IOP elevation from 1 to 24 hours, while administration 3 hours postoperatively reduced the IOP elevation at 5 hours or more after surgery.
Statin Eligibility Under American and European Cholesterol Guidelines
Authors: Erling Falk, Martin Bødtker Mortensen
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Genetic Control of Fatty Acid Metabolism, Especially Study of Genetic Control of Cholesterol
Authors: Goro Mimura
Journal: Circulation (1975)

The serum cholesterol of 1431 inhabitants over 10 years old in the general population was estimated by the method of Autoanalyzer. The correlation coefficients of the serum total cholesterol between parent and child and between siblings were obtained from other samples which completely excluded consanguinity. The genetic study of 41 pedigrees of familial hypercholesterolemia with xanthoma which described the cholesterol value of parent and child in Japan and other countries was done, and the following results were obtained. 1) Cholesterol is a quantitative character, there-fore it will be controlled genetically by polygene. 2) It was presumed that the mode of inheritance of Type 11 hypercholesterolemia (with or without xanthoma) was also controlled by polygene. 3) The correlation coefficients of cholesterol between parent and child and between siblings were found to be 0.26004, 0.27998, respectively. 4) The heritability of cholesterol was found to be 0.5995.
Pharmacological IRS1/2 Inhibition Reduces Cell Viability in BCR-ABL1 Positive Cells
Authors: Renata Scopim-Ribeiro, João Agostinho Machado-Neto, Paula de Melo Campos, Adriana da Silva Santos Duarte, Priscila Santos Scheucher, Amélia Góes, Sara Teresinha Olalla Saad, Belinda Pinto Simoes, Eduardo Magalhães Rego, Fabiola Traina
Journal: Blood (2015)
A Blood Borne Biomarker of Cell Death (nucleosomal DNA) Is An Early Predictor of End of Treatment Response to Chemotherapy in Lymphoma
Authors: Alastair P Greystoke, Kim Linton, James O’Connor, Ben Taylor, Tim Ward, Fran Maders, Caroline Hamer, Tim Illidge, Malcolm Ranson, Andrew Hughes, Alan Jackson, Caroline Dive, John Radford
Journal: Blood (2008)
Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS
Authors: Seung-Ah Yahng, Yoo-Jin Kim, Jae-Ho Yoon, Seung-Hwan Shin, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Seok Lee, Chang-Ki Min, Hee-Je Kim, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park
Journal: Blood (2011)
Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis from An Ongoing Multicenter Phase II Trial.
Authors: Christophe Ferme, Maria Victoria Mateos, Sergio Szyldergemajn, Emanuele Zucca, Jose Espinoza, Javier Briones, Franck Morschhauser, Christian Gisselbrecht, Vincent Ribrag
Journal: Blood (2008)
Effect Size Estimation in Neuroimaging
Authors: Marianne C. Reddan, Martin A. Lindquist, Tor D. Wager
Journal: JAMA Psychiatry (2017)

A central goal of translational neuroimaging is to establish robust links between brain measures and clinical outcomes.Success hinges on the development of brain biomarkers with large effect sizes.With large enough effects, a measure may be diagnostic of outcomes at the individual patient level.Surprisingly, however, standard brain-mapping analyses are not designed to estimate or optimize the effect sizes of brain-outcome relationships, and estimates are often biased.Here, we review these issues and how to estimate effect sizes in neuroimaging research.Effect size is a unit-free description of the strength of an effect, independent of sample size.Examples include Cohen d, Pearson r, and number needed to treat. 1,2For a given sample size (N), these can be converted to a t or z score (eg, Cohen d is t/[N] 1/2 ).But t, z, F, and P values are sample size dependent and relate to the presence of an effect (statistical significance), not its magnitude.By contrast, effect size describes a finding's practical significance, which determines its clinical importance.This is an important distinction because small effects can reach statistical significance given a large enough sample, even if they are unlikely to be of practical importance or replicable across diverse samples. 3raditional neuroimaging studies are not designed to estimate effect sizes.A typical analysis tests for effects at each of 50 000 to 350 000 brain voxels.Post hoc effect sizes are selectively reported for a small subset of significant voxels.This practice creates bias, making effect size estimates larger than their true values. 4 It is like a mediocre golfer who plays 5000 holes over the course of his career but only reports his 10 best holes.Bias is introduced because the best performance, selected post hoc, is not representative of expected performance.The Figure shows a simulation in which the true effect size in a set of voxels is d = 0.5.Once noise is added and a statistical test (t test) is conducted across 30 individuals, all significant voxels have an estimated effect size greater than the true effect.Why does this occur?Voxels tend to be significant if they show a true effect and have noise that favors the hypothesis.Correcting for multiple comparisons reduces false positives but actually increases this optimistic bias. 6As statistical thresholds become more stringent, an increasingly small subset of tests with favorable noise will reach significance, making the estimated post hoc effect size grow.In sum, conducting a large number of tests inher-
Hepatic macrophage activation is associated with adipose tissue insulin resistance in non-diabetic patients with Non-Alcoholic Fatty Liver Disease
Authors: Chiara Rosso, K. Kazankov, Milena Marietti, M. Gaggini, E. Buzzigoli, H. J. Møller, Gian Paolo Caviglia, Maria Lorena Abate, Antonina Smedile, Giorgio Maria Saracco, H. Vilstrup, A. Gastaldelli, J. George, H. Grønbæk, Elisabetta Bugianesi
Journal: Hepatology (2016)
Reduced Intensity Conditioning (RIC) and Hematopoietic Stem Cell Transpalntation (HSCT) Utilizing Extracorporeal Photopheresis (ECP), Fludarabine, and Targeted Dose Busulfan in Children.
Authors: Jennifer Schneiderman, Reggie Duerst, Kim Campbell, Amy Krutsick, William Tse, Kimberly Thormann, Morris Kletzel, David A. Jacobsohn
Journal: Blood (2006)
Novel Evidence That a Lipolytic Enzyme - Hematopoietic-Specific Phospholipase C Beta 2 - Promotes Mobilization of Hematopoietic Stem Cells By Decreasing Their Lipid Raft-Mediated Bone Marrow Retention and Increasing the Pro-Mobilizing Effects of Granulocytes
Authors: Mateusz Adamiak, Agata Poniewierska-Baran, Gabriela Schneider, Ahmed Abdelbaset-Ismail, Malwina Suszynska, Ahmed Abdel-Latif, Magdalena Kucia, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2015)
Effect of Substituting 50% Isovue for Sterile Water as the Delivery Medium for SIR-Spheres
Authors: Cherng Chao, S. William Stavropoulos, Jeffrey I. Mondschein, Mandeep Dagli, Deepak Sudheendra, Gregory Nadolski, Michael C. Soulen
Journal: Clinical Nuclear Medicine (2017)

Purpose The objective of this study was to evaluate the effect of substituting 50% Isovue (Bracco Diagnostics Inc, Monroe Township, NJ) for sterile water on the delivery of 90Y resin microspheres (SIR-Spheres [Sirtex Medical Limited, Sydney, Australia]). Materials and Methods The authors retrospectively reviewed all SIR-Spheres radioembolizations at the authors' institution from January 1, 2011, to February 10, 2014. From January 1, 2011, to April 30, 2013, all users performed SIR-Spheres radioembolization per the manufacturer's original instructions using sterile water in the B and D lines and intermittently checking the progress of the embolization by injecting contrast via the B line. Beginning May 1, 2013, a modified technique using Isovue diluted 50% with saline in place of sterile water in both the B and D lines of the infusion set. The authors compared the prepared versus administered activity of 90Y SIR-Spheres, fluoroscopy time, administration time, and frequency of radioembolizations terminated for stasis when using water versus dilute contrast in the B and D lines. Results One hundred seventy-five radioembolizations were performed, 132 (75%) with water as the delivery medium and 43 (25%) with 50% contrast as delivery medium. The mean percentage of the 90Y activity administered was 98% with contrast versus 87% with water (P < 0.01). More than 95% of cases using contrast resulted in 90% or more delivery of the prepared 90Y activity versus 59% of cases with water (P < 0.01). For cases using water, 17% were terminated for stasis, whereas 2% (1 case) using contrast was terminated for stasis. The mean 90Y administration time was 7 minutes with contrast versus 22 minutes with water (P = 0.015). Excluding the 37 cases involving coil embolization, the mean fluoroscopy time was 8.3 minutes with contrast versus 11.5 minutes with water (P < 0.05). No complications occurred with the contrast method; however, there were 4 complications with water, including 1 nontarget gastric ulceration. Conclusions Using dilute contrast as the delivery medium for SIR-Spheres resulted in a significantly greater percentage of the prepared activity administered to the patient with substantially shorter administration time. Termination for stasis occurred less often with dilute contrast. No complications were observed when using dilute contrast, which allowed continuous real-time monitoring of the 90Y microsphere administration.
Constitutive Cyclin A1 Expression Inhibits Cytosine Arabinoside-Induced Apoptosis in Myeloid Leukemia Cells.
Authors: Tsuyoshi Nakamaki, Kunihiko Fukuchi, Hidetoshi Nakashima, Norimichi Hattori, Takashi Maeda, Hirotsugu Ariizumi, Daisuke Adachi, Bungo Saito, Takaji Yanagisawa, Isao Matsuda, Shigeru Tomoyasu
Journal: Blood (2008)
The Immunogenicity of Red Blood Cell Antigens in Relation to Antigen Exposure
Authors: Dorothea Evers, Rutger Middelburg, Masja De Haas, Saurabh Zalpuri, Karen de Vooght, Daan van de Kerkhof, Otto Visser, Nathalie Pequeriaux, Francisca Hudig, Henk Schonewille, Jaap Jan Zwaginga, Anske van der Bom
Journal: Blood (2015)
Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)
Authors: Hady Ghanem, Hagop M. Kantarjian, Richard E. Champlin, Lakshmikanth Katragadda, Gabriela Rondon, Elias J. Jabbour, Alfonso Quintás-Cardama, Sherry A. Pierce, Jorge E. Cortes
Journal: Blood (2012)
Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma.
Authors: Ronald Walker, Erik Rasmussen, Laurie Jones-Jackson, Elias J. Anaissie, Terri L. Alpe, Joshua Epstein, Frits Van Rhee, Maurizio Zangari, Guido Tricot, John Shaughnessy, Bart Barlogie
Journal: Blood (2005)
Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial
Authors: Tammy L. Sirich, Kara Fong, Brett Larive, Gerald J. Beck, Glenn M. Chertow, Nathan W. Levin, Alan S. Kliger, Natalie S. Plummer, Timothy W. Meyer
Journal: Kidney International (2017)
<i>AHRR</i>(cg05575921) hypomethylation marks smoking behaviour, morbidity and mortality
Authors: Stig E Bojesen, Nicholas Timpson, Caroline Relton, George Davey Smith, Børge G Nordestgaard
Journal: Thorax (2017)

<h3>Rationale and objectives</h3> Self-reported smoking underestimates disease risk. Smoking affects DNA methylation, in particular the cg05575921 site in the aryl hydrocarbon receptor repressor <i>(AHRR</i>) gene. We tested the hypothesis that <i>AHRR</i> cg05575921 hypomethylation is associated with risk of smoking-related morbidity and mortality. <h3>Methods</h3> From the Copenhagen City Heart Study representing the Danish general population, we studied 9234 individuals. Using bisulphite treated leucocyte DNA, <i>AHRR</i> (cg05575921) methylation was measured. Rs1051730 (<i>CHRN3A</i>) genotype was used to evaluate smoking heaviness. Participants were followed for up to 22 years for exacerbations of COPD, event of lung cancer and all-cause mortality. Six-year lung cancer risk was calculated according to the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO<sub>M2012</sub>). <h3>Measurements and main results</h3> <i>AHRR</i> (cg05575921) hypomethylation was associated with former and current smoking status, high daily and cumulative smoking, short time since smoking cessation (all p values &lt;7×10<sup>–31</sup>), and the smoking-related <i>CHRN3A</i> genotype (−0.48% per T-allele, p=0.002). The multifactorially adjusted HRs for the lowest versus highest methylation quintiles were 4.58 (95% CI 2.83 to 7.42) for COPD exacerbations, 4.87 (2.31 to 10.3) for lung cancer and 1.67 (1.48 to 1.88) for all-cause mortality. Finally, among 2576 high-risk smokers eligible for lung cancer screening by CT, observed cumulative incidences of lung cancer after 6 years for individuals in the lowest and highest methylation quintiles were 3.7% and 0.0% (p=2×10<sup>–7</sup>), whereas predicted PLCO<sub>M2012</sub> 6-year risks were similar (4.3% and 4.4%, p=0.77). <h3>Conclusion</h3> <i>AHRR</i> (cg05575921) hypomethylation, a marker of smoking behaviour, provides potentially clinical relevant predictions of future smoking-related morbidity and mortality.
Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score
Authors: Prashant Deshpande, Punit Jain, Ansu Abu Alex, Anu Korula, Kavitha M Lakshmi, Nisham P N, Fouzia NA, Aby Abraham, Alok Srivastava, Poonkuzhali Balasubramanian, Biju George, Vikram Mathews
Journal: Blood (2015)
Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes
Authors: Gert Mayer, Hiddo J.L. Heerspink, Constantin Aschauer, Andreas Heinzel, Georg Heinze, Alexander Kainz, Judith Sunzenauer, Paul Perco, Dick de Zeeuw, Peter Rossing, Michelle Pena, Rainer Oberbauer
Journal: Diabetes Care (2017)

OBJECTIVE Chronic kidney disease (CKD) in diabetes has a complex molecular and likely multifaceted pathophysiology. We aimed to validate a panel of biomarkers identified using a systems biology approach to predict the individual decline of estimated glomerular filtration rate (eGFR) in a large group of patients with type 2 diabetes and CKD at various stages. RESEARCH DESIGN AND METHODS We used publicly available “omics” data to develop a molecular process model of CKD in diabetes and identified a representative parsimonious set of nine molecular biomarkers: chitinase 3-like protein 1, growth hormone 1, hepatocyte growth factor, matrix metalloproteinase (MMP) 2, MMP7, MMP8, MMP13, tyrosine kinase, and tumor necrosis factor receptor-1. These biomarkers were measured in baseline serum samples from 1,765 patients recruited into two large clinical trials. eGFR decline was predicted based on molecular markers, clinical risk factors (including baseline eGFR and albuminuria), and both combined, and these predictions were evaluated using mixed linear regression models for longitudinal data. RESULTS The variability of annual eGFR loss explained by the biomarkers, indicated by the adjusted R2 value, was 15% and 34% for patients with eGFR ≥60 and &amp;lt;60 mL/min/1.73 m2, respectively; variability explained by clinical predictors was 20% and 31%, respectively. A combination of molecular and clinical predictors increased the adjusted R2 to 35% and 64%, respectively. Calibration analysis of marker models showed significant (all P &amp;lt; 0.0001) but largely irrelevant deviations from optimal calibration (calibration-in-the-large: −1.125 and 0.95; calibration slopes: 1.07 and 1.13 in the two groups, respectively). CONCLUSIONS A small set of serum protein biomarkers identified using a systems biology approach, combined with clinical variables, enhances the prediction of renal function loss over a wide range of baseline eGFR values in patients with type 2 diabetes and CKD.
Lipoprotein lipase (LPL) activity is decreased in CAD patients and inversely correlated with severity of angina pectoris and silent myocardial ischemia
Authors: Jjp Kastelein, JW Jukema, AJ van Boven, H Jansen, AH Zwinderman, TJ Rabelink, Rjg Peters, KI Lie, Avg Bruschke, Hayden
Journal: Circulation (1998)
Relationship Between Intestinal Marginal Zone B-Cell Lymphoma and Enterobacterias Including Camphylobacter Jejuni
Authors: Sung Yong Oh, Won Seog Kim, Seok Jin Kim, Junshik Hong, Soon Il Lee, Jae Hoon Lee, Young Rok Do, Min Kyung Kim, Ho Sup Lee, Cheolwon Suh, Seong Yoon Yi, Jong Hyun KIm, sook Hee Hong
Journal: Blood (2011)